Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 8/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | GBA1 | P04062 | 1/20 | 0.37 |
| ▸ | MGLL | Q99685 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14997773 | 1.00 | DNM1 (0.50) | DNM1TSHRTHRBCA12CA1 | |
| SCHEMBL26264322 | 1.00 | DNM1 (0.50) | DNM1TSHRTHRBCA12CA1 | |
| SCHEMBL10705836 | 1.00 | DNM1 (0.50) | DNM1TSHRTHRBCA12CA1 | |
| Nonane SCHEMBL28466423 | 1.00 | DNM1 (0.50) | DNM1TSHRTHRBCA12CA1 | |
| SCHEMBL28190831 | 1.00 | DNM1 (0.50) | DNM1TSHRTHRBCA12CA1 | |
| SCHEMBL14997774 | 1.00 | DNM1 (0.50) | DNM1TSHRTHRBCA12CA1 | |
| Hydrochloric Acid SCHEMBL6892416 | 0.97 | DNM1 (0.52) | DNM1TSHRTHRBCA12CA1 | |
| Hydrochloric Acid SCHEMBL6890708 | 0.97 | DNM1 (0.52) | DNM1TSHRTHRBCA12CA1 | |
| Hydrochloric Acid SCHEMBL6890293 | 0.97 | DNM1 (0.52) | DNM1TSHRTHRBCA12CA1 | |
| Hydrochloric Acid SCHEMBL6891923 | 0.97 | DNM1 (0.52) | DNM1TSHRTHRBCA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295075-A1 | LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS | Acuitas Therapeutics, Inc. (CA) | 2023-09-21 | — | — | US | disclosed |
| US-20230295075-A1 | LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS | Acuitas Therapeutics, Inc. (CA) | 2023-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295075-A1 | LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS | PHOSPHO1, SGMS1, NPC1 | DNM1 939/4885TSHR 2371/4885THRB 1890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.